(Q37730010)

22 August 2017

1 reference

title

Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials (English)

1 reference

22 August 2017

0 references

0 references

Eric Siemers

1

1 reference

22 August 2017

Ronald B DeMattos

series ordinal

2

1 reference

22 August 2017

Patrick C May

series ordinal

3

1 reference

22 August 2017

Robert A Dean

series ordinal

4

1 reference

22 August 2017

1 February 2010

1 reference

22 August 2017

Biomarkers in Medicine

1 reference

22 August 2017

4

1 reference

22 August 2017

1

1 reference

22 August 2017

81-89

1 reference

The role of biomarkers in clinical trials for Alzheimer disease

22 August 2017

1 reference

Presenilin: running with scissors in the membrane

21 January 2018

1 reference

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

New pathways in drug discovery for Alzheimer's disease

21 January 2018

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system

21 January 2018

1 reference

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

21 January 2018

1 reference

Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers

21 January 2018

1 reference

Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease

21 January 2018

1 reference

Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase

21 January 2018

1 reference

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease

21 January 2018

1 reference

Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

21 January 2018

1 reference

The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression

21 January 2018

1 reference

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

Variations in the neuropathology of familial Alzheimer's disease

21 January 2018

1 reference

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits.

21 January 2018

1 reference

Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain.

21 January 2018

1 reference

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

21 January 2018

1 reference

Amyloid precursor protein trafficking, processing, and function

21 January 2018

1 reference

Microtubule-associated protein tau as a therapeutic target in neurodegenerative disease

21 January 2018

1 reference

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

21 January 2018

1 reference

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease

21 January 2018

1 reference

Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231.

21 January 2018

1 reference

Tau-mediated neurodegeneration in Alzheimer's disease and related disorders

21 January 2018

1 reference

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

21 January 2018

1 reference

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease.

21 January 2018

1 reference

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

21 January 2018

1 reference

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/BMM.09.85

1 reference

22 August 2017

1 reference